Figure 3

High IGFBP7 expression is predictive for poor outcome. IGFBP7 expression was analysed in CD138+ purified MM cells of newly diagnosed, previously untreated myeloma patients of the Heidelberg-Montpellier group (HM; n = 247), as well as for validation purposes in the independent Little-Rock (LR; n = 701) patient cohort as depicted in the Methods section. In both patient series, high IGFBP7 expression was associated with worse event-free (A, C) and overall survival (B, D).